Quality of life with second- or third-line nab-paclitaxel–based regimens in advanced non-small cell lung cancer
Ponce Aix S., TALBOT D., Ramaswamy G., Cobo M., Postmus PE., Lewanski C., Bennouna J., Fischer JR., Juan-Vidal O., Stewart DJ., Ardizzoni A., Bhore R., Wolfsteiner M., Reck M., Jin Ong T., Morgensztern D.
Aim: Evaluate quality of life (QOL) in patients with advanced non-small cell lung cancer treated with second- or third-line nab-paclitaxel ± durvalumab. Patients & Methods: Longitudinal QOL was assessed using LCSS, EQ-5D-5L, and EORTC QLQ-C30. Results: QOL was generally stable through 8 treatment cycles (both arms). Clinically meaningful improvement from baseline was noted in LCSS (overall constitutional score and 3-item index [nab-paclitaxel + durvalumab]) and EORTC QLQ-C30 (global health status/QOL and emotional functioning [both arms] and pain [nab-paclitaxel + durvalumab]) analyses. EQ-5D-5L domains were stable/improved or completely resolved at least once in 19% to 56% and 9% to 51% of patients, respectively. Conclusion: While QOL trends were promising, additional data are required to support these regimens in this setting. Keywords (maximum of 10): nab-paclitaxel, durvalumab, quality of life, non-small cell lung cancer, Lung Cancer Symptom Scale, EQ-5D-5L, EORTC QLQ-C30